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Gelsolin is an important cytoskeletal protein of platelets and studies have shown a close relationship between gelsolin and cardio-
vascular disease. However, the role of gelsolin in the development of coronary heart disease (CHD) is unclear. In this study, we 
record the distribution of gelsolin in human platelets and plasma and its association with different types of CHD. This study in-
cluded 114 cases, with 33 stable angina pectoris (SAP) cases, 81 acute coronary syndrome (ACS) cases—composed of 39 unsta-
ble angina pectoris (UAP) and 42 acute myocardial infarction (AMI) cases, and 31 healthy control participants. Gelsolin concen-
tration in platelet rich plasma (PRP) and platelet poor plasma (PPP), actin filament (F-actin) and Gc-globulin of PPP were deter-
mined by enzyme-linked immunoadsorbent assay (ELISA). The fluorescence intensity of CD62p and cytoplasmic calcium 
([Ca2+]i) in human platelets measured by flow cytometry. We also used turbidimetry to detect the platelet aggregation rate (PAR). 
We analyzed the correlation between platelet gelsolin concentration and CD62p or plasma F-actin levels among each different 
patient group. Compared with the control group, the gelsolin level in PRP of UAP and AMI groups increased significantly 
(P<0.01), while the gelsolin level in PPP of all the three patient groups decreased markedly (P<0.01), and the CD62p, PAR, 
[Ca2+]i of platelets, F-actin and Gc-globulin of the UAP and AMI groups increased significantly (P<0.01). Compared with the 
SAP group, the gelsolin level in PRP, the PAR, [Ca2+]i of platelets and CD62p of other two groups increased significantly 
(P<0.01), F-actin of the AMI group increased markedly (P<0.01). Platelet cytoskeleton protein dynamics vary among the differ-
ent types of CHD. Platelet gelsolin levels are markedly increased and accompanied by increased platelet activity, F-actin and 
[Ca2+]i of ACS patients, while gelsolin levels in PPP are markedly lower. Abnormally increased platelet gelsolin levels show high 
positive correlation with the level of platelet activity. Therefore, platelet gelsolin might be a novel molecular marker and/or a new 
potential therapeutic target of anti-platelet therapy of ACS.  
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Coronary heart disease (CHD) remains a major global pub-
lic health problem. Platelets play an important role in he-
mostasis but are also responsible for the formation of path-
ogenic thrombi underlying acute clinical manifestations of 
vascular atherothrombotic disease. Multiple pathways, in-
cluding adenosine diphosphate (ADP), thromboxane A2 
(TXA2), and thrombin are capable of activating platelets. 
Deregulated platelet activation can lead to the formation of 
platelet-rich thrombi that occlude the arterial lumen and are 
capable of causing ischemia and cardiovascular events. Oral 
antiplatelet drugs are a milestone in the therapy of cardio-
vascular atherothrombotic diseases. The efficacy of an-
tiplatelet drugs, such as aspirin and clopidogrel, in decreas-
ing the risk of adverse events in CHD patients has been well 
studied in the past 20 years. Despite oral antiplatelet therapy, 
a number of adverse CHD events continue to occur. In re-
cent years, many reports have shown a possible relationship 
between residual platelet activity, as measured by a variety 
of laboratory tests, and clinical outcomes; raising the possi-
bility that “resistance” to oral antiplatelet drugs may under-
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lie many such adverse events [1]. These phenomena suggest 
that other pathways capable of stimulating platelet activa-
tion may exist. It is therefore meaningful to identify new 
therapeutic targets for anti-platelet therapy for CHD. 
Using differential proteomics in platelets, our previous 
studies [2] found that gelsolin protein levels show the high-
est difference between the platelets of CHD patients and 
healthy controls. This suggests that the platelet cytoskeleton 
may play an important role in CHD development. Based on 
previous results, this paper further studied the distribution 
of gelsolin in human platelets and plasma, and studied any 
potential correlation with different types of CHD to verify 
the role of platelet gelsolin in CHD development. 
1  Methods 
1.1  Diagnostic criteria 
Patient diagnosis meet the standards established under the 
ACC/AHA/ACP-ASIM Guidelines (1999) [3] for the man-
agement of patients with chronic stable angina, and the 
ACC/AHA Guidelines (2002) [4] for the management of 
patients with unstable angina and non-ST-segment elevation 
myocardial infarction. We selected those patients having 
symptoms of angina and/or objective evidence of myocar-
dial ischemia and those with at least one marked coronary 
stenosis (>50%) shown by coronary arteriography examina-
tion.  
1.2  Inclusion and exclusion criteria 
The inclusion standard required that patients must meet all 
the following criteria, namely, (1) falls under one of the 
various classifications of ischemic heart diseases; (2) suf-
fering from angina pectoris symptoms and/or showing signs 
of myocardial ischemia; (3) latest coronary arteriography 
examination showing significant stenosis (>50%); and, (4) 
age between 35 to 75 years. 
Patients who met any one of the following conditions 
were excluded: severe valvuloplasty, diabetes mellitus type 
I, presence of severe primary diseases of the liver, kidney, 
hemopoietic system, presence of malignant tumors, calcium 
channel blockers (CCB) administration in the last two 
weeks, inability to obtain informed consent or deemed poor 
compliance case, participation in other clinical trials, and 
pregnant or lactating women. 
Subjects enrolled in the healthy control group (31 cases) 
were identified as healthy by history and physical examina-
tion. Tests included routine blood count, liver function, 
chest X-ray, and electrocardiograph (ECG), no history of 
prior administration of drugs affecting atherosclerotic or 
thrombotic processes in the last two weeks, no history of 
significant mental or physical diseases nor history of famil-
iar or self-psychiatric illnesses. This study is in accordance 
with the Helsinki Declaration [5], with no contravention to 
medical ethics. 
1.3  Blood preparation 
Fresh blood (12 mL) was drawn from an antecubital vein 
and collected into vacutainer tubes containing acid-citrate- 
dextrose (ACD) 9% v/v (trisodium citrate 22.0 g/L, citric 
acid 8.0 g/L, dextrose 24.5 g/L) as anticoagulant, and the 
initial 2 mL of blood discarded to avoid spontaneous plate-
let activation. We collected the blood of patients before an-
tithrombotic therapy and angiography examination. The 
blood was centrifuged for 10 min at 150 ×g at room tem-
perature to obtain platelet-rich plasma (PRP) and the re-
maining blood centrifuged for 20 min at 800 ×g to obtain 
platelet poor plasma (PPP). 
1.4  Determination of CD62p expression in platelets 
We determined the level of platelet activation, as repre-
sented by the fluorescent intensity of platelet glycoprotein 
CD62p, by flow cytometry (EPICS Elite, Beckman Coulter 
Inc., Fullerton, CA, USA). We mixed the blood evenly and 
completed the following procedures within 4 h. Control and 
test tubes containing 50 L of blood had 20 L of homotype 
control CD61-FITC/CD62p-PE (CD61-FITC, Anti-GPIIIa, 
Cat: 348093; CD62p-PE, Anti-GMP-140, Cat: 348107; Bec-
ton Dickinson Co., Franklin Lakes, NJ, USA) added. Sam-
ples were mixed evenly by light shaking, and incubated in 
darkness at room temperature for 20 min. One milliliter of 
cold (2–8°C) fixative liquid was added into each tube, mixed 
well and incubated again in darkness at 2–8°C for 30 min. 
Samples were then analyzed by flow cytometry to measure 
the mean fluorescence intensity (MFI) of CD62p. We used 
multi-parameter and multi-fluorescent flow cytometry with 
standard fluorescent micro-balloon adopted to correct the 
beam path and stream. Test data was obtained by Forward 
Scatter (FSC) vs. Side Scattering (SSC) gate, flow cytome-
try special software (Expo32, Beckman Coulter Inc.). 
1.5  Determination of platelet aggregation rate (PAR) 
We determined the PAR among different patients groups 
using turbidimetry (Platelet Aggregation Instrument, LBY- 
NJ2, Beijing Lipusheng Co., China). The inducer of platelet 
aggregation is arachidonic acid (AA, Helena Biosciences 
Co., Sunderland, Tyne and Wear, UK). 
1.6  Determination of [Ca2+]i in platelets 
Platelet-rich plasma was prepared and incubated with 4 mol/L 
Fluo-3-AM (Sigma, Saint Louis, MO, USA) at 37°C for  
40 min. The Ca2+ concentration of platelets was determined 
using flow cytometry to measure their MFI, as previously 
described [6]. The platelet Ca2+ concentration (nmol/L) is 
calculated as [Ca2+]i = Kd × (F  Fmin)/(Fmax  F) [7]. 
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1.7  Determination of gelsolin, F-actin and Gc-globulin 
The plasma concentration (PRP and PPP) of gelsolin (Cat: 
E0372h, R&D Co., Minneapolis, MN, USA), F-actin (Cat: 
E1876h, R&D Co.) and Gc-globulin (Cat: E1910h, R&D 
Co.) were determined by enzyme-linked immunoadsorbent 
assay (ELISA), as per the manufacturer’s instructions. 
1.8  Statistical analysis 
Statistical analysis was conducted using SPSS 13.0 software 
package. Data are expressed as mean ± standard deviation 
( x ± s) or counts (percentage), unless otherwise specified. 
We used Chi-square or rank sum test to evaluate enumera-
tion data. For measurement data, we used variance analysis 
or t-tests. We assessed correlations of platelet gelsolin with 
other variables by Spearman correlation coefficient and 
unitary linear regression. A P-value of <0.05 was consid-
ered statistically significant. 
2  Results 
2.1  General clinical materials 
All CHD patients enrolled were in-patients admitted from 
August 2010 to February 2011 in Beijing Anzhen Hospital 
of Capital Medical University and were diagnosed and as-
signed to the SAP (33 cases), UAP (39 cases) and AMI (42 
cases) groups accordingly. 
There was no statistical difference among the three groups 
in age, sex and platelet count (P>0.05). The risk factors 
(smoking, hypertension, dyslipidemia and diabetes history), 
location of affected coronary artery and medication history 
(statins and aspirin) was comparable among the three 
groups (P>0.05) (Table 1). 
2.2  Comparison of plasma gelsolin concentration of 
CHD patients among each patient group 
Compared with the control group, the gelsolin concentration 
in the PRP of the UAP and AMI groups was significantly 
higher (P<0.01), while that in the PPP of the three patients 
groups decreased markedly (P<0.01). Compared with the 
SAP group, the gelsolin concentration in the PRP of the 
UAP and AMI groups was significantly higher (P<0.01) 
(Table 2). 
2.3  Comparison of CD62p and [Ca2+]i of platelets for 
CHD patients among each patient group 
Compared with healthy controls, the CD62p and [Ca2+]i of 
platelets was significantly higher (P<0.01) among the three  
Table 1  Clinical features of each study groups 
Parameter 
CHD patients Control group 
(31 cases) SAP group (33 cases) UAP group (39 cases) AMI group (42 cases) 
Age (years, x ± s) 54.0 ± 6.5 52.5 ± 5.5 51.5 ± 7.5 50.5 ± 8.0 
Male/females (case) 26/7 30/9 35/7 23/8 
Risk factor [case (%)]     
Hypertension 15 (45.5) 17 (43.6) 20 (47.6) 0 
Dyslipidemia 14 (42.4) 17 (43.6) 19 (45.2) 0 
Diabetes 4 (12.1) 4 (10.3) 5 (11.9) 0 
Current smokers 22 (66.7) 25 (64.1) 29 (69.05) 0 
Medication [case (%)]     
Aspirin 20 (60.6) 24 (61.5) 26 (61.9) 0 
Statins 13 (39.4) 15 (38.5) 17 (40.5) 0 
Single-vessel disease [case (%)] 12 (36.4) 15 (38.5) 16 (38.1) 0 
Multi-vessel disease [case (%)] 21 (63.6) 24 (61.5) 26 (61.9) 0 
Platelet count (×103/L) 214 ± 56.9 215 ± 38.8 216 ± 22.8 210.9 ± 42.7 
Table 2  Comparison of plasma gelsolin concentration among different patient groups ( x ± s, g/mL)a) 
Group Case PRP PPP 
SAP 33 105.13±15.27** 109.17±18.12** 
UAP 39 128.23±17.55**†† 112.58±11.47** 
AMI 42 162.16±21.07**†† 112.40±8.66** 
Control 31 117.55±9.91 121.44±6.77 
a) **, P<0.01, compared with the control group; ††, P<0.01, compared with the SAP group.  
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patient groups. Compared with the SAP group, the CD62p 
and [Ca2+]i of platelets among the UAP and AMI groups 
was significantly higher (P<0.01) again (Figures 1 and 2). 
2.4  Comparison of PAR for CHD patients among each 
patient group 
Compared with healthy controls, the PAR of the three pa-
tient groups was markedly increased (P<0.01). Compared 
with the SAP group, the PAR of the UAP and AMI groups 
was significantly increased (P<0.01) again (Figure 3). 
2.5  Comparison of F-actin and Gc-globulin concentra-
tion for CHD patients among each patient group 
Compared with healthy controls, the F-actin of the UAP and 
AMI groups was significantly increased (P < 0.05 and P < 
0.01 respectively). The Gc-globulin of the three CHD 
groups was also significantly higher (P<0.01). Compared 
with the SAP group, the F-actin of the AMI group was sig-
nificantly increased (P < 0.01). However, the Gc-globulin of 
the other two groups was not statistically different (P > 0.05) 
(Figure 4). 
 
Figure 1  Comparison of CD62p of platelet for CHD patients among different groups (mean ± standard deviation). SAP group, 12.97%±4.01%; UAP group, 
18.62%±4.05%; AMI group, 20.54%±6.75%; Control group, 5.55%±2.20%. **, P＜0.01, compared with the control group; ††, P<0.01, compared with the 
SAP group.  
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Figure 2  Comparison of [Ca2+]i of platelet for CHD patients among different groups (mean ± standard deviation). SAP group, 258.22±30.19 nmol/L; UAP 
group, 315.98±28.88 nmol/L; AMI group, 352.51±32.51 nmol/L; Control group, 109.62±9.84 nmol/L. **, P < 0.01, compared with the control group; ††, P < 
0.01, compared with the SAP group.  
2.6  Analyses of correlations between platelet gelsolin 
concentration and CD62p or plasma F-actin levels among 
each patient group 
Next, we investigated any potential correlation between the 
platelet gelsolin concentration and CD62p or plasma F-actin 
levels that may exist between the SAP, UAP and AMI groups. 
Correlation analysis showed that platelet gelsolin concen-
trations were high positively correlated with CD62p or 
plasma F-actin levels in each of the three patient groups 
(Figure 5). 
3  Discussion 
CHD is a leading cause of death in many developed coun-
tries. It is increasingly clear that cardiovascular outcomes 
depend on an understanding of the biology of CHD, which 
may involve vascular inflammation, endothelial dysfunction, 
and plaque instability [8], among others. Activated platelets 
play a pivotal role in the formation of arterial thrombi [9]. 
CD62p (P-selection) is a 140 kD glycoprotein that is present 
in the granules of platelets and translocates rapidly to the  
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Figure 3  Comparison of platelet aggregation rate (PAR) for CHD pa-
tients among different groups (mean ± standard deviation). SAP group, 
30.18%±2.6%; UAP group, 39.07%±3.41%; AMI group, 64.29%±5.67%; 
Control group, 20%±2.93%. **, P<0.01, compared with the control group; 
††, P<0.01, compared with the SAP group.  
 
Figure 4  Comparison of F-actin and Gc-globulin concentration for CHD 
patients among different groups (mean ± standard deviation). (a) Plasma 
F-actin concentration for CHD patients among different groups. SAP group, 
1.29±0.29 mol/mL; UAP group, 1.41±0.31 mol/mL; AMI group, 2.01± 
0.46 mol/mL; CONTROL group, 1.27±0.25 mol/mL. (b) Plasma Gc- 
globulin concentration for CHD patients among different groups. SAP 
group, 220±26.78 g/mL; UAP group, 218.27±27.30 g/mL; AMI group, 
224.49±32.73 g/mL; CONTROL group, 181.81±37.67 g/mL. *, P < 0.05, 
**, P < 0.01, compared with control group;
 ††, P < 0.01, compared with 
SAP group.  
cell surface after platelet activation, and is generally con-
sidered to be the gold marker of platelet activation [10,11]. 
There is evidence that patients with various types of CHD, 
including stable [12] and unstable [13] angina and acute 
myocardial infarction [14] have increased CD62p levels. 
Among all types of CHD, symptomatic stable angina is a 
clinical expression of myocardial ischemia associated with 
fixed atherosclerotic coronary stenosis; however, patients 
with acute coronary syndrome (ACS) constitute the major 
proportion of persons who require admission to cardiac 
units for urgent care, including invasive treatment and ag-
gregate anticoagulant and antiplaque drug therapy [15]. In 
this study, our results were consistent with these observa-
tions, indicating that varying degrees of platelet activation 
appear in all types of CHD and that ACS (including unsta-
ble angina and non-ST elevation MI) has a higher level of 
platelet activation and PAR compared with that of stable 
angina. These findings suggest an important role for CD62p 
in the arterial thrombosis of ACS. 
Platelet activation not only causes membrane protein 
change, but also a series of morphological changes, from 
inviscid, discotic circulating platelets into a paste-like, pro-
truding platelet jelly, that depends on the regulation of 
platelet cytoskeletal proteins. 
Over the past ten years, laboratories have successfully 
applied proteomics technology to platelet research, contrib-
uting to the emerging field of platelet proteomics. Those 
studies led to the identification of a considerable number of 
novel platelet proteins, many of which have been studied 
further at a functional level [16]. Our previous study [2] had 
identified gelsolin as having the greatest difference in ex-
pression levels between the platelets of CHD patients and 
healthy subjects. However, the role of platelet gelsolin in 
the development of CHD is unclear. 
Gelsolin is a calcium-activated F-actin severing and cap-
ping protein found in many cell types and that is expressed 
as both cytoplasmic and plasma isoforms, and is an im-
portant cytoskeletal protein [17]. Two regulatory mecha-
nisms are thought to modulate gelsolin activity in vivo. Cal-
cium activates gelsolin to allow capping and severing of 
F-actin, while phosphatidylinositol-4,5-bisphosphate (PIP2) 
at the cell membrane keeps gelsolin sequestered in an inac-
tive state. Upon hydrolysis of PIP2, gelsolin is released into 
the cytoplasm and Ca2+ dependent activation can occur [18]. 
Previous work on gelsolin has mainly focused on the calcium 
regulated remodeling of F-actin, while more recent data has 
begun to elucidate the importance of gelsolin-mediated 
function in pathological conditions, including cardiovascu-
lar disease [19]. 
During tissue injury and cell death, actin is released into 
the circulation where it can interact with components of the 
haemostatic and fibrinolytic systems, or polymerize and 
form F-actin. In vitro studies [20] have suggested that F-actin 
can lead to platelet aggregation directly, and the presence of 
F-actin in blood vessels, which can plug smaller vessels and 
decrease blood flow to promote the formation of blood clots, 
can be fatal. Infusion of high doses of G-actin in rabbits 
caused the rapid and fatal formation of massive actin fila-
ment-containing thrombi in arterioles and capillaries of  
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Figure 5  Analysis of correlations between platelet gelsolin concentration and CD62p or plasma F-actin level among different groups. (a) SAP group 
(n=33); (b) UAP group (n=39); (c) AMI group (n=42).  
pulmonary veins, as well as endothelial injury [21]. An ac-
tin scavenger system [22] is therefore likely to exist, plasma 
gelsolin, together with Gc-globulin, another extracellular 
actin-binding protein, were regarded as potentially important 
components of this system: capable of removing F-actin 
from the circulation and inhibiting F-actin elongation. 
Our results were consistent with previous studies and 
showed that the gelsolin concentration of PPP decreased in 
SAP and ACS patients [23]. ACS is often associated with 
the rupture of vulnerable atherosclerotic plaques and coro-
nary thrombus formation, leading to adverse outcomes. The 
results of this study clearly demonstrated that actin is re-
leased into the bloodstream, leading to accumulation of 
F-actin at the higher level of platelet activation of ACS, and 
that circulating actin concentrations in excess of plasma 
gelsolin or Gc-globulin have prothrombotic or cytotoxic 
activities resulting in the severe depletion of plasma gelsolin. 
Gc-globulin (vitamin D binding protein) is a multifunctional 
protein [24]; its main physiological importance is probably 
the binding of actin, or binding and transportation of vita-
min D analogous. Interestingly, in this study we observed 
that the plasma of CHD patients contains greater amounts of 
Gc-globulin compared with healthy subjects. Previous stud-
ies [25] demonstrated that three vitamin D binding protein 
isotypes were increased in asprin-resistant CHD patients 
and this could reduce the inhibitory effect of asprin on 
thromboxane A2 production. Thus, this may suggest that the 
increased Gc-globulin level in this study may be associated 
with a large number of asprin-resistant patients included in 
our study or with increased reactively due to sudden severe 
depletion.  
Another finding from our present study is the different 
levels of gelsolin in human platelet and plasma. Namely, an 
increase in platelet gelsolin levels, which was in agreement 
with our findings from a study of platelet proteomics [2], 
and a decrease in plasma gelsolin levels in ACS patients, 
compared to healthy subjects and stable angina patients. An 
analysis between platelet gelsolin concentrations and 
CD62p showed that platelet gelsolin levels have a high pos-
itive correlation with the level of platelet activation in ACS. 
Calcium ions not only promote gelsolin secretion but also 
play a vital role in the development of platelet activation. 
Studies have shown increased platelet [Ca2+]i in patients 
with CHD [26], and that calcium chelators can reduce 
platelet [Ca2+]i and inhibit platelet aggregation [27]. Our 
results showed an increased platelet [Ca2+]i in ACS com-
pared with healthy subjects and stable angina patients. The 
increased calcium influx in platelets could be one of the 
main mechanisms causing the abnormally increased platelet 
gelsolin levels observed in ACS. 
Previous research has focused on gelsolin’s possible role 
in cardiovascular diseases; several directions are currently 
being explored to test whether gelsolin itself can be used as 
a therapeutic molecule [28]. Our findings provide further 
insight into the important role of platelet gelsolin in the 
process of platelet activation in ACS. In this study, we have 
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shown that platelet cytoskeletal proteins vary between dif-
ferent types of CHD, manifested mainly in gelsolin and 
F-actin. It is likely that plasma gelsolin clears away a great 
deal of F-actin released into circulation, and this is con-
sistent with a role as an actin scavenger. At the onset of 
ACS, plasma gelsolin levels diminish significantly, while 
platelet gelsolin level increased abnormally, accompanied 
by an increased level of platelet activation and calcium in-
flux. Platelet gelsolin levels are more highly correlated with 
ACS, compared to SAP. Therefore, does platelet gelsolin 
represent a novel therapeutic target of anti-platelet activa-
tion in ACS? We believe this is a significant area of further 
study, and it will be our research direction in the future. 
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